Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
NUTRAPLUS PR ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NUTRAPLUS PR Mar-20 |
ADCOCK INGRAM Jun-14 |
NUTRAPLUS PR/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 22 | 321 | - | |
Low | Rs | 5 | 232 | - | |
Sales per share (Unadj.) | Rs | 25.6 | 95.5 | - | |
Earnings per share (Unadj.) | Rs | -14.0 | -24.1 | - | |
Cash flow per share (Unadj.) | Rs | -12.7 | -20.0 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 6.3 | 75.0 | - | |
Shares outstanding (eoy) | m | 34.09 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.5 | 2.9 | 18.4% | |
Avg P/E ratio | x | -1.0 | -11.5 | 8.5% | |
P/CF ratio (eoy) | x | -1.1 | -13.9 | 7.8% | |
Price / Book Value ratio | x | 2.1 | 3.7 | 58.3% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 464 | 46,656 | 1.0% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 73 | 2,928 | 2.5% | |
Avg. sales/employee | Rs Th | 0 | 3,756.2 | - | |
Avg. wages/employee | Rs Th | 0 | 682.1 | - | |
Avg. net profit/employee | Rs Th | 0 | -946.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 873 | 16,125 | 5.4% | |
Other income | Rs m | 1 | 113 | 1.3% | |
Total revenues | Rs m | 875 | 16,238 | 5.4% | |
Gross profit | Rs m | -358 | -2,794 | 12.8% | |
Depreciation | Rs m | 47 | 696 | 6.8% | |
Interest | Rs m | 74 | 437 | 17.0% | |
Profit before tax | Rs m | -478 | -3,814 | 12.5% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 238 | 0.0% | |
Profit after tax | Rs m | -478 | -4,063 | 11.8% | |
Gross profit margin | % | -41.0 | -17.3 | 236.8% | |
Effective tax rate | % | 0 | -6.2 | 0.0% | |
Net profit margin | % | -54.8 | -25.2 | 217.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 178 | 11,810 | 1.5% | |
Current liabilities | Rs m | 890 | 6,645 | 13.4% | |
Net working cap to sales | % | -81.5 | 32.0 | -254.5% | |
Current ratio | x | 0.2 | 1.8 | 11.3% | |
Inventory Days | Days | 1 | 111 | 0.6% | |
Debtors Days | Days | 11,562,625 | 124 | 9,329,244.5% | |
Net fixed assets | Rs m | 939 | 6,884 | 13.6% | |
Share capital | Rs m | 170 | 75 | 227.7% | |
Net worth | Rs m | 216 | 12,657 | 1.7% | |
Long term debt | Rs m | 2 | 4,448 | 0.0% | |
Total assets | Rs m | 1,117 | 23,909 | 4.7% | |
Interest coverage | x | -5.4 | -7.7 | 70.3% | |
Debt to equity ratio | x | 0 | 0.4 | 2.7% | |
Sales to assets ratio | x | 0.8 | 0.7 | 116.0% | |
Return on assets | % | -36.2 | -15.2 | 238.5% | |
Return on equity | % | -221.3 | -32.1 | 689.2% | |
Return on capital | % | -185.1 | -19.8 | 934.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 91 | 1,376 | 6.6% | |
From Investments | Rs m | -27 | -423 | 6.4% | |
From Financial Activity | Rs m | -76 | 4,037 | -1.9% | |
Net Cashflow | Rs m | -12 | 4,990 | -0.2% |
Compare NUTRAPLUS PR With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare NUTRAPLUS PR With: ADESHWAR MEDITEX SOTAC PHARMACEUTICALS LTD. PFIZER UNJHA FORMUL AVON ORGANIC
Asian stocks inched higher on Tuesday as investors awaited a slew of economic data, corporate earnings and the U.S. Federal Reserve's policy meeting.